Revolution Medicines (RVMD) Payables (2019 - 2026)

Revolution Medicines has reported Payables for 8 years, with the latest figure at $88.4 million in Q2 2026.

• On a quarterly basis, Payables rose 55.77% year-over-year to $88.4 million in Q2 2026; TTM through Jun 2026 was $88.4 million, a 55.77% increase from a year earlier, with the FY2025 full-year figure at $64.6 million, up 18.72% from the prior year.
• Payables was $88.4 million for Q2 2026 at Revolution Medicines, up from $80.5 million in the prior quarter.
• The five-year high for Payables was $88.4 million in Q2 2026, with the low at $14.1 million in Q2 2022.
• Average Payables over 5 years is $42.7 million, with a median of $31.1 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Payables retreated 17.45% in 2024, then soared 206.06% in 2025.
• Over 5 years, Payables stood at $21.3 million in 2022, then soared by 190.0% to $61.8 million in 2023, then declined by 11.91% to $54.4 million in 2024, then increased by 18.72% to $64.6 million in 2025, then surged by 36.84% to $88.4 million in 2026.
• The last three Payables figures came in at $88.4 million (Q2 2026), $80.5 million (Q1 2026), and $64.6 million (Q4 2025), per Business Quant data.